These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31352120)

  • 21. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK.
    Oh J; Seo DW; Diaz T; Wei B; Ward Y; Ray JM; Morioka Y; Shi S; Kitayama H; Takahashi C; Noda M; Stetler-Stevenson WG
    Cancer Res; 2004 Dec; 64(24):9062-9. PubMed ID: 15604273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting a Designer TIMP-1 to the Cell Surface for Effective MT1-MMP Inhibition: A Potential Role for the Prion Protein in Renal Carcinoma Therapy.
    Jiang B; Liu J; Lee MH
    Molecules; 2019 Jan; 24(2):. PubMed ID: 30641935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Xenopus tissue inhibitor of metalloproteinases-2: a role in regulating matrix metalloproteinase activity during development.
    Fu L; Sun G; Fiorentino M; Shi YB
    PLoS One; 2012; 7(5):e36707. PubMed ID: 22693555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substrate choice of membrane-type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase-2 levels.
    Kudo T; Takino T; Miyamori H; Thompson EW; Sato H
    Cancer Sci; 2007 Apr; 98(4):563-8. PubMed ID: 17425593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
    Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
    Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells.
    Zhong J; Gencay MM; Bubendorf L; Burgess JK; Parson H; Robinson BW; Tamm M; Black JL; Roth M
    J Cell Physiol; 2006 May; 207(2):540-52. PubMed ID: 16447244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.
    Vaillant C; Didier-Bazès M; Hutter A; Belin MF; Thomasset N
    J Neurosci; 1999 Jun; 19(12):4994-5004. PubMed ID: 10366632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of TIMP-2, MT1-MMP, and MMP-2 expression during C2C12 differentiation.
    Lluri G; Jaworski DM
    Muscle Nerve; 2005 Oct; 32(4):492-9. PubMed ID: 16003733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of MT1-MMP and TIMP-2 in human periodontal disease.
    Oyarzún A; Arancibia R; Hidalgo R; Peñafiel C; Cáceres M; González MJ; Martínez J; Smith PC
    Oral Dis; 2010 May; 16(4):388-95. PubMed ID: 20233321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.
    Jo Y; Yeon J; Kim HJ; Lee ST
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):511-9. PubMed ID: 10642509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of matrix metalloproteinase (TIMP)-2 during bovine placentation and at term with or without placental retention.
    Dilly M; Hambruch N; Shenavai S; Schuler G; Froehlich R; Haeger JD; Ozalp GR; Pfarrer C
    Theriogenology; 2011 Apr; 75(6):1104-14. PubMed ID: 21247626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.
    Aricò A; Giantin M; Gelain ME; Riondato F; Comazzi S; Rütgen BC; Essler SE; Dacasto M; Castagnaro M; Aresu L
    BMC Vet Res; 2013 May; 9():94. PubMed ID: 23641796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of a latent soluble form of membrane type 1 matrix metalloprotease bound with tissue inhibitor of matrix metalloproteinases-2 in periprosthetic tissues and fluids from loose arthroplasty endoprostheses.
    Niarakis A; Giannopoulou E; Ravazoula P; Panagiotopoulos E; Zarkadis IK; Aletras AJ
    FEBS J; 2013 Dec; 280(24):6541-55. PubMed ID: 24112707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional characterization of tissue inhibitor of metalloproteinase-1 (TIMP-1) N- and C-terminal domains during Xenopus laevis development.
    Nieuwesteeg MA; Willson JA; Cepeda M; Fox MA; Damjanovski S
    ScientificWorldJournal; 2014; 2014():467907. PubMed ID: 24616631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of RECK and MMPs in Hepatoblastoma and Neuroblastoma and Comparative Analysis on the Tumor Metastasis.
    Xu M; Wang HF; Zhang HZ
    Asian Pac J Cancer Prev; 2015; 16(9):4007-11. PubMed ID: 25987077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways.
    Miki T; Takegami Y; Okawa K; Muraguchi T; Noda M; Takahashi C
    J Biol Chem; 2007 Apr; 282(16):12341-52. PubMed ID: 17329256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells.
    Remacle AG; Shiryaev SA; Golubkov VS; Freskos JN; Brown MA; Karwa AS; Naik AD; Howard CP; Sympson CJ; Strongin AY
    J Biol Chem; 2013 Jul; 288(28):20568-80. PubMed ID: 23733191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.
    Oh J; Takahashi R; Kondo S; Mizoguchi A; Adachi E; Sasahara RM; Nishimura S; Imamura Y; Kitayama H; Alexander DB; Ide C; Horan TP; Arakawa T; Yoshida H; Nishikawa S; Itoh Y; Seiki M; Itohara S; Takahashi C; Noda M
    Cell; 2001 Dec; 107(6):789-800. PubMed ID: 11747814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells.
    Cepeda MA; Pelling JJ; Evered CL; Williams KC; Freedman Z; Stan I; Willson JA; Leong HS; Damjanovski S
    Mol Cancer; 2016 Oct; 15(1):65. PubMed ID: 27756325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of RECK levels in
    Willson JA; Bork BS; Muir CA; Damjanovski S
    J Biol Res (Thessalon); 2019 Dec; 26():16. PubMed ID: 31799217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.